SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

1

Hematopoietic stem cell transplant and CAR-T therapy recipients are at high risk for severe COVID-19, with mortality rates exceeding 18% during early pandemic waves.
2

Vaccination with mRNA vaccines generates a strong antibody response in these patients, but concerns exist regarding the waning of SARS-CoV-2-reactive antibody titers over time.
3

Emerging variants like Omicron may reduce vaccine efficacy, prompting recommendations for booster doses to enhance antibody titers in immunocompromised individuals.
4

The study aims to evaluate antibody kinetics and breakthrough infection rates in hematopoietic stem cell transplant recipients one year post-vaccination.
5

A total of 1783 vaccinated hematological patients were registered, with 572 selected to assess antibody dynamics and breakthrough infection incidence.

Bone Marrow Transplantation

by José Luis Piñana, Rodrigo Martino, Lourdes Vazquez, Lucia López-Corral, Ariadna Pérez, Pedro Chorão, Alejandro Avendaño-Pita, María-Jesús Pascual, Andrés Sánchez-Salinas, Gabriela Sanz-Linares, María T. Olave, Ignacio Arroyo, Mar Tormo, Lucia Villalon, Venancio Conesa-Garcia, Beatriz Gago, María-José Terol, Marta Villalba, Valentín Garcia-Gutierrez, Almudena Cabero, José Ángel Hernández-Rivas, Elena Ferrer, Irene García-Cadenas, Anabel Teruel, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano
February 28, 2023

1